Ongoing Research

 
News Articles for Ongoing Research top ^
2014/7/23
Inter Parfums, Inc. (NASDAQ GS:IPAR) today announced that for the three months ended June 30, 2014, net sales of the Company’s ongoing brands (excluding Burberry brand sales) increased 22.1% to $118.2 million, as compared to $96.8 million for the corresponding period of the prior year.
Sign-up for Inter Parfums, Inc. Reports 22% Increase in Second Quarter Sales from Ongoing Brands investment picks
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, reported pre-clinical data and early clinical observations from an ongoing Phase 1 trial, being conducted in collaboration with Eisai, the Institut Gustave Roussy, and the Institut Bergonie, of EZH2 inhibitor EPZ-6438 (E7438) in patients with advanced solid tumors and B-cell lymphomas.
Sign-up for Epizyme Presents Pre-Clinical Data and Early Clinical Observations from Ongoing Phase 1 Trial of EZH2 Inhibitor EPZ-6438 (E7438) at ASH Meeting on Lymphoma Biology investment picks
LEXINGTON, Mass., June 30, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCBB:XBIO) , a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, today announced results from its ongoing data analysis of the first cohort of its Phase 2, sequential multiple dose study evaluating the safety and efficacy of ErepoXen ® , subcutaneously administered polysialylated erythropoietin (PSA-EPO), for the treatment of anemia in Chronic Kidney Disease (CKD) patients who are neither on dialysis nor receiving erythropoiesis stimulating agents.
Sign-up for Xenetic Biosciences Announces Ongoing Safety Data From Phase 2 Trial of ErepoXen(R) investment picks
In order to enhance statistical powering and expedite recruitment, RedHill has increased the number of subjects and clinical sites, respectively, in the ongoing RHB-105 Phase III ERADICATE Hp study, with top-line data currently expected in the first half of 2015 FDA has permitted RedHill to pursue with RHB-105 a significantly broader indication than that of existing H.
Sign-up for RedHill Biopharma Provides Update on Expansion of Ongoing RHB-105 Phase III Study, Targeting Broadened H. pylori Indication Authorized by FDA investment picks
2014/8/13
Phase III Trial Is Alive And Well; "Hint Of Failure" A Complete Fabrication; No Interim Analysis of Efficacy Done; 55 Patients' Positive Data Independently Collected.
Sign-up for NW BIO CORRECTS ONGOING FALSE CLAIMS BY FEUERSTEIN ABOUT PHASE III TRIAL OF DCVAX®-L, AND INTERIM ANALYSIS investment picks
http://media.marketwire.com/attachments/201408/78171_xenetic.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1136809&ProfileId=051205&sourceType=1 LEXINGTON, MA --
Sign-up for Xenetic Biosciences Announces Ongoing Safety and Efficacy Data From Phase 2 Trial of ErepoXen(R) investment picks
JACKSONVILLE, Fla., June 23, 2014 (GLOBE NEWSWIRE) -- ParkerVision, Inc. (Nasdaq:PRKR) (the "Company") announced today that on Friday, June 20, United States District Judge Roy B.
Sign-up for ParkerVision Received District Court Rulings in Ongoing Litigation Against Qualcomm investment picks
http://media.marketwire.com/attachments/201211/99925_41732_threshold.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1129483&ProfileId=051205&sourceType=1 SOUTH SAN FRANCISCO, CA --
Sign-up for Threshold Announces Initiation of Dosing With TH-302/Bortezomib (Velcade(R))/Dexamethasone ("TBorD") in Final Stage of Ongoing Phase 1/2 Trial of Patients With Relapsed/Refractory Multiple Myeloma investment picks
Clinical Activity of G-202 to be presented at session for Treatment for Intermediate-Advanced Stage Disease SAN ANTONIO , July 7, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces that interim data from the G-202 Phase I and Phase II trials in hepatocellular carcinoma (HCC) patients will be presented at the Fifth Annual Asia-Pacific Primary Liver Cancer Expert (APPLE) Meeting to be held July 11-13 th in Taipei , Taiwan.
Sign-up for GenSpera To Present Ongoing HCC Trial Data at APPLE 2014 Congress July 12th in Taipei investment picks
2014/7/7
Voip-Pal.com Inc. ("Voip-Pal", "Company") (OTC Pink: VPLM) announced today that a written offer has been received to monetize its telephony technology.
Sign-up for Voip-Pal.com, Inc. Receives an Offer to Monetize its Technology; Discussions for Potential Acquisition and or Joint Venture Partnerships are Ongoing as Blackout Period Comes to an End investment picks
2014/7/2
VANCOUVER , July 2, 2014 /PRNewswire/ - Golden Queen Mining Co.
Sign-up for Golden Queen secures an advance with Leucadia and Auvergne for the ongoing development of its Soledad Mountain Project investment picks
2014/8/20
SYDNEY--PanAust Ltd.
Sign-up for PanAust's Takeover Talks Ongoing, Profits Fall investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Ongoing Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: ONEOK Partners  |  Next: Online Banking